aTyr Pharma: stockholders approve potential 1-for-10 to 1-for-50 reverse split

What happened aTyr Pharma filed an 8-K reporting that, on Oct 16, 2026, at its 2026 Special Meeting of Stockholders the company's stockholders approved a series of alternate amendments to the company's restated certificate of incorporation to effect, at the option of the company's board of directors, a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-50, inclusive. As of the Sep 4, 2026 record date, 98,087,425 shares of the company's common stock were outstanding and entitled to vote. A total of 57,915,370 shares were present or represented by valid proxy, representing approximately 59.04% of shares outstanding.

Key details

• Proposal: Proposal 1 to approve alternate amendments to the restated certificate of incorporation to allow a reverse stock split between 1-for-10 and 1-for-50, inclusive, at the board's option.
• Vote totals: Votes for 52,451,734; votes against 5,234,645; abstentions 228,991; broker non-votes 2.
• Record and meeting dates: Record date Sep 4, 2026; special meeting held Oct 16, 2026.
• Shares outstanding and present: 98,087,425 shares outstanding; 57,915,370 shares present or represented by proxy (59.04%).

Why it may matter The 8-K reports Item 5.07, submission of matters to a vote of security holders, and discloses the vote on amendments that would permit the board to implement a reverse stock split between 1-for-10 and 1-for-50. This filing does not show why the company acted.